A robotic-assisted biopsy is being touted as a game-changing advance in diagnosing lung cancer, following a first-of-its-kind UK trial that shows promise for faster, more precise tissue sampling in the lungs.
The technique lets clinicians steer extremely fine movements inside the lungs to biopsy tiny, suspicious areas that are often too difficult to reach with standard methods. By accessing these smaller nodules, doctors can obtain a diagnosis earlier rather than merely monitoring the nodules over time.
Experts describe the approach as a major shift in how lung cancer is diagnosed. For patients, the method could alleviate the anxiety of waiting months for a follow-up scan and may improve survival by enabling quicker treatment decisions.
The trial enrolled 200 NHS patients at Royal Brompton Hospital and St Bartholomew’s Hospital who had nodules detected on lung imaging. The researchers used the Ion endoluminal system (Ion), created by Intuitive, to generate a detailed map of the lungs from the scan data—an approach likened to a GPS route for the procedure.
Using this map, clinicians navigated a robotic catheter, inserted through the throat, directly to the target nodule to perform the biopsy.
Professor Pallav Shah, a respiratory physician at Royal Brompton, explained that the robotic guidance allows for micro-movements that place the biopsy tool precisely within the small lesion, achieving greater accuracy than traditional methods.
Results published in Thorax show the robotic-assisted process yielded a diagnostic outcome that was correct in 92% of cases. In 99% of patients, the biopsy tool was positioned accurately within the suspicious nodule.
Lung cancer remains the third most common cancer in the UK, with more than 49,000 new cases and about 33,000 deaths annually. A targeted screening program launched in 2023 aims to detect the disease earlier.
For smaller nodules around 8 millimeters in size, conventional practice often involved waiting a year before another scan. The researchers argue that robotics can shorten or eliminate that waiting period by delivering a timely tissue diagnosis.
Prof. Shah noted that this technology makes screening more meaningful because it moves beyond merely spotting a nodule to actively diagnosing and guiding treatment sooner, which could reduce patient anxiety and improve outcomes.
Kelvin Lau, a clinical director and thoracic surgeon at St Bartholomew’s, called the Ion-assisted approach a paradigm shift. He emphasized that while screening helps identify nodules, the crucial next step is determining which ones are cancerous and acting quickly.
At St Bartholomew’s, patients no longer wait months for repeat scans; they can receive a biopsy the same day, resume normal activities shortly after, and begin appropriate treatment sooner—avoiding unnecessary surgeries.
Prof. Shah expressed optimism that the technology could be scaled across the NHS, noting that other health systems have successfully implemented similar solutions. He mentioned that since the trial, more than 900 Ion procedures have been performed at Royal Brompton.
In response to the findings, Paula Chadwick of the Roy Castle Lung Cancer Foundation highlighted that early and accurate diagnosis is key to improving survival. She argued that robotic-assisted bronchoscopy could transform the patient experience by delivering quicker answers and enabling earlier access to curative treatment. The organization urged continued innovation to promote earlier detection and save more lives.
This evolving approach invites discussion: will widespread adoption of robotic-assisted biopsy reshape standard lung cancer pathways, or will cost, training, and access create new disparities? Share your thoughts on where this technology should fit in national screening and diagnostic protocols.
